|1.||Qadri, Firdausi: 22 articles (10/2013 - 08/2003)|
|2.||Holmgren, Jan: 17 articles (01/2014 - 08/2002)|
|3.||Calderwood, Stephen B: 16 articles (10/2013 - 08/2003)|
|4.||Ryan, Edward T: 16 articles (10/2013 - 08/2003)|
|5.||Harris, Jason B: 13 articles (05/2012 - 08/2005)|
|6.||Holmgren, J: 11 articles (07/2013 - 10/2000)|
|7.||Chowdhury, Fahima: 11 articles (05/2012 - 11/2005)|
|8.||Khan, Ashraful I: 9 articles (05/2010 - 08/2005)|
|9.||Yuki, Yoshikazu: 7 articles (09/2015 - 12/2005)|
|10.||Kiyono, Hiroshi: 7 articles (09/2015 - 12/2005)|
10/17/2005 - "Owing to the antigenic similarity between cholera toxin and LT, immunization with inactivated oral B-subunit/whole-cell cholera vaccine (BS-WC) offers short term (3 months) but significant (>67%) protection against TD caused by LT-related ETEC. "
09/01/1990 - "The B subunit portion of cholera toxin (CTB) is a safe and effective oral immunizing agent in humans, affording protection against both cholera and diarrhoea caused by enterotoxigenic Escherichia coli producing heat-labile toxin (LT) (Clemens et al., 1986; 1988). "
06/01/1983 - "These results confirm a protective role for mucosal antitoxin in experimental cholera and show that procholeragenoid is both safe and effective as an oral immunogen. "
06/01/2006 - "The licensure in the European Union of a killed whole cell cholera vaccine combined with the recombinant B subunit of cholera toxin (rCTB-WC) has stimulated interest in protection against cholera. "
04/01/2011 - "The results of this study suggest that altered El Tor biotype V. cholerae with the classical cholera toxin gene are involved in cholera outbreaks in India."
04/01/2014 - "Intranasal immunization with inactivated SPY1 plus cholera toxin adjuvant elicited effective serotype-independent protection against the colonization of pneumococcal strains 19F and 4 as well as lethal infection of pneumococcal serotypes 2, 3, 14, and 6B. "
07/01/2011 - "Vaccine-induced protection against H pylori infection and its local and systemic immunological correlates were assessed in animal models, using cholera toxin or CAF01 as adjuvants. "
02/20/2006 - "Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection."
02/01/2004 - "Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection."
10/01/1988 - "Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit."
01/01/1983 - "In field trials, immunization with procholeragenoid markedly decreased the incidence of diarrhea (85%) and death (84%) due to colibacillosis in neonatal piglets. "
02/01/1992 - "However, volunteer studies have shown that these non-cholera toxin-producing strains still provoke mild to moderate diarrhea in some individuals. "
04/01/1984 - "A randomized, controlled field trial was performed to test the ability of B subunit, the nontoxic, binding portion of cholera toxin, to block the toxin receptors (GM1 ganglioside) in the small intestine and thereby prevent diarrhea in individuals infected with Vibrio cholerae O1. "
03/01/1982 - "In three independent field trials, immunization with procholeragenoid resulted in a substantial decrease in diarrhea (73% in controls versus 11% in immunized) and death (4.7% in controls versus 0.77% in immunized) in neonatal piglets. "
11/04/2015 - "In addition, the effect of CG against secretory diarrhea was investigated using a model of fluid secretion in cholera toxin-treated intestinal closed loops in live mice. "
|4.||Human Influenza (Influenza)
01/01/1992 - "Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit."
06/01/1990 - "Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination."
01/01/1990 - "Enhancement of DTH response by cholera toxin B subunit inoculated intranasally together with influenza HA vaccine."
12/01/1989 - "Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB."
08/01/1989 - "The effectiveness of the two-dose regimen, composed of a primary intranasal inoculation of influenza A-type virus HA vaccine together with B subunit of cholera toxin (CTB) and the subsequent intranasal inoculation of vaccine alone 4 weeks later, was examined. "
05/01/2014 - "Furthermore, it was demonstrated that cholera toxin downregulated the activation of the c-Raf/Mek/Erk cascade, an important mediator of tumor cell proliferation, via the PKA-dependent c-Raf phosphorylation at Ser-43. "
01/01/2011 - "Here we investigate the effect of cholera toxin B (CTB) and temperature on two pathological model systems: urothelial cell line RT4, as a model system of a benign tumor, and urothelial cell line T24, as a model system of a metastatic tumor. "
01/01/2011 - "Temperature and cholera toxin B are factors that influence formation of membrane nanotubes in RT4 and T24 urothelial cancer cell lines."
02/01/2008 - "The data demonstrate that a bacterial live vaccine encompassing T1SS in combination with cholera toxin subunit B can be successfully used for delivery of PSA to induce cytotoxic CD8+ T-cell responses resulting in an efficient prevention of tumor growth in mice."
08/11/1993 - "The effects of a differentiating agent (cholera toxin) and/or a tumor promoter (12-O-tetradecanoyl-phorbol-13-acetate) were also examined. "
|3.||Immunoglobulin A (IgA)
|6.||Immunoglobulin G (IgG)
|8.||Membrane Proteins (Integral Membrane Proteins)
|1.||Fluid Therapy (Oral Rehydration Therapy)